These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37024412)

  • 61. Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system.
    Chen C; Fu F; Ding L; Fang J; Xiao J
    Front Immunol; 2022; 13():938322. PubMed ID: 36172346
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military.
    Montgomery J; Ryan M; Engler R; Hoffman D; McClenathan B; Collins L; Loran D; Hrncir D; Herring K; Platzer M; Adams N; Sanou A; Cooper LT
    JAMA Cardiol; 2021 Oct; 6(10):1202-1206. PubMed ID: 34185045
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [A rare case of myocarditis and pulmonary embolism after BNT162b2 mRNA vaccine].
    Mancini N; Cortigiani L; Aquaro G; Bovenzi FM
    G Ital Cardiol (Rome); 2022 Apr; 23(4):244-246. PubMed ID: 35343473
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Herpes zoster and simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis.
    Gringeri M; Battini V; Cammarata G; Mosini G; Guarnieri G; Leoni C; Pozzi M; Radice S; Clementi E; Carnovale C
    Expert Rev Vaccines; 2022 May; 21(5):675-684. PubMed ID: 35191364
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273).
    Préta LH; Contejean A; Salvo F; Treluyer JM; Charlier C; Chouchana L
    Br J Clin Pharmacol; 2022 Jul; 88(7):3529-3534. PubMed ID: 35174524
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS).
    Moro PL; Ennulat C; Brown H; Woody G; Zhang B; Marquez P; Woo EJ; Su JR
    Drug Saf; 2024 May; 47(5):487-493. PubMed ID: 38411838
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
    Tompkins LK; Baggs J; Myers TR; Gee JM; Marquez PL; Kennedy SB; Peake D; Dua D; Hause AM; Strid P; Abara W; Rossetti R; Shimabukuro TT; Shay DK
    Vaccine; 2022 Dec; 40(52):7653-7659. PubMed ID: 36372665
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines.
    Sessa M; Kragholm K; Hviid A; Andersen M
    Expert Opin Drug Saf; 2021 Nov; 20(11):1451-1453. PubMed ID: 34264151
    [No Abstract]   [Full Text] [Related]  

  • 69. COVID-19 Vaccine Safety First Year Findings in Adolescents.
    Hesse EM; Hause A; Myers T; Su JR; Marquez P; Zhang B; Cortese MM; Thames-Allen A; Curtis CR; Maloney SA; Thompson D; Nair N; Alimchandani M; Niu M; Gee J; Shay DK; Shimabukuro TT;
    Pediatrics; 2023 May; 151(5):. PubMed ID: 37082919
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
    Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
    PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Adverse Events Following Immunization With mRNA and Viral Vector Vaccines in Individuals With Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection From the Canadian National Vaccine Safety Network.
    Bettinger JA; Irvine MA; Shulha HP; Valiquette L; Muller MP; Vanderkooi OG; Kellner JD; Top KA; Sadarangani M; McGeer A; Isenor JE; Marty K; Soe P; De Serres G;
    Clin Infect Dis; 2023 Mar; 76(6):1088-1102. PubMed ID: 36310514
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Observed-over-Expected analysis as additional method for pharmacovigilance signal detection in large-scaled spontaneous adverse event reporting.
    van der Boom MDX; van Eekeren R; van Hunsel FPAM
    Pharmacoepidemiol Drug Saf; 2023 Jul; 32(7):783-794. PubMed ID: 36919526
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.
    Deng L; Glover C; Dymock M; Pillsbury A; Marsh JA; Quinn HE; Leeb A; Cashman P; Snelling TL; Wood N; Macartney K
    Med J Aust; 2022 Aug; 217(4):195-202. PubMed ID: 35781813
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273.
    Teo SP
    J Pharm Pract; 2022 Dec; 35(6):947-951. PubMed ID: 33840294
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Reporting rates for VAERS death reports following COVID-19 vaccination, December 14, 2020-November 17, 2021.
    Day B; Menschik D; Thompson D; Jankosky C; Su J; Moro P; Zinderman C; Welsh K; Dimova RB; Nair N
    Pharmacoepidemiol Drug Saf; 2023 Jul; 32(7):763-772. PubMed ID: 36813704
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Safety Signal Generation for Sudden Sensorineural Hearing Loss Following Messenger RNA COVID-19 Vaccination: Postmarketing Surveillance Using the French Pharmacovigilance Spontaneous Reporting Database.
    Thai-Van H; Valnet-Rabier MB; Anciaux M; Lambert A; Maurier A; Cottin J; Pietri T; Destère A; Damin-Pernik M; Perrouin F; Bagheri H
    JMIR Public Health Surveill; 2023 Jul; 9():e45263. PubMed ID: 37071555
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions.
    Haq HN; Khan H; Chaudhry H; Nimmala S; Demidovich J; Papudesi BN; Potluri SD
    J Natl Med Assoc; 2022 Dec; 114(6):601-612. PubMed ID: 36511275
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Assessment of Sudden Sensorineural Hearing Loss After COVID-19 Vaccination.
    Formeister EJ; Wu MJ; Chari DA; Meek R; Rauch SD; Remenschneider AK; Quesnel AM; de Venecia R; Lee DJ; Chien W; Stewart CM; Galaiya D; Kozin ED; Sun DQ
    JAMA Otolaryngol Head Neck Surg; 2022 Apr; 148(4):307-315. PubMed ID: 35201274
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study.
    Yechezkel M; Mofaz M; Painsky A; Patalon T; Gazit S; Shmueli E; Yamin D
    Lancet Respir Med; 2023 Feb; 11(2):139-150. PubMed ID: 36410364
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series.
    Fazlollahi A; Zahmatyar M; Noori M; Nejadghaderi SA; Sullman MJM; Shekarriz-Foumani R; Kolahi AA; Singh K; Safiri S
    Rev Med Virol; 2022 Jul; 32(4):e2318. PubMed ID: 34921468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.